| __timestamp | Halozyme Therapeutics, Inc. | Viatris Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 22732000 | 4050200000 |
| Thursday, January 1, 2015 | 29245000 | 5047100000 |
| Friday, January 1, 2016 | 33206000 | 6078400000 |
| Sunday, January 1, 2017 | 31152000 | 6931500000 |
| Monday, January 1, 2018 | 10136000 | 6861900000 |
| Tuesday, January 1, 2019 | 45546000 | 7056300000 |
| Wednesday, January 1, 2020 | 43367000 | 8149300000 |
| Friday, January 1, 2021 | 81413000 | 12310800000 |
| Saturday, January 1, 2022 | 139304000 | 9765700000 |
| Sunday, January 1, 2023 | 192361000 | 8988300000 |
| Monday, January 1, 2024 | 159417000 |
Cracking the code
In the ever-evolving pharmaceutical landscape, understanding cost structures is crucial. Over the past decade, Viatris Inc. and Halozyme Therapeutics, Inc. have showcased distinct financial trajectories. Viatris, a global healthcare giant, consistently reported a cost of revenue averaging around $7.5 billion annually, peaking in 2021 with a 23% increase from 2014. In contrast, Halozyme, a smaller biotech firm, demonstrated a more dynamic growth, with its cost of revenue surging by over 740% from 2014 to 2023. This stark contrast highlights the differing scales and strategies of these companies. While Viatris's costs reflect its expansive operations, Halozyme's rising expenses indicate aggressive growth and innovation. As the industry continues to adapt, these insights offer a glimpse into the financial strategies shaping the future of healthcare.
Johnson & Johnson vs Viatris Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: AbbVie Inc. and Viatris Inc.
Cost of Revenue Trends: Amgen Inc. vs Halozyme Therapeutics, Inc.
Cost of Revenue Trends: Bristol-Myers Squibb Company vs Halozyme Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Gilead Sciences, Inc. vs Halozyme Therapeutics, Inc.
Cost of Revenue: Key Insights for Biogen Inc. and Viatris Inc.
Comparing Cost of Revenue Efficiency: Viatris Inc. vs Corcept Therapeutics Incorporated
Cost of Revenue Trends: BioMarin Pharmaceutical Inc. vs Halozyme Therapeutics, Inc.
Cost of Revenue: Key Insights for Halozyme Therapeutics, Inc. and Corcept Therapeutics Incorporated
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Veracyte, Inc.'s Expenses
Cost of Revenue: Key Insights for Halozyme Therapeutics, Inc. and HUTCHMED (China) Limited
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Agios Pharmaceuticals, Inc.'s Expenses